ACHE
ENSG00000087085
Target class
Enzyme
Chromosome
7
Approved drugs
19
Clinical candidates (approved and in development)
23
- Approved drugs
- 19
- Clinical candidates (approved and in development)
- 23
- Chemical probe available
- Yes
- Target name
- ACHE
- Gene name
- Acetylcholinesterase (Yt blood group)
- Gene symbol
- ACHE
- Previous gene symbols
- YT
- Protein name
- Acetylcholinesterase (AChE) (EC 3.1.1.7)
- Gene biotype
- Protein coding
- Gene family
- Blood group antigens|Cholinesterase family
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 49
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 71.17
- Tissue specificity (Gini)
- 0.627
- Tissue specificity (tau)
- 0.879
- KEGG gene identifiers
- hsa:43
- Protein interaction confidence
- 0.822033
- Protein interaction partners
- 30
- R-HSA-112311
- R-HSA-1483191
- R-HSA-422085
- End position
- 100897022
- Start position
- 100889994
- Chromosome
- 7
- Strand
- Reverse
- Synapse . Secreted . Cell membrane
- Peripheral membrane protein .
- SUBCELLULAR LOCATION: [Isoform T]: Nucleus. Note=Only observed in apoptotic nuclei.
- SUBCELLULAR LOCATION: [Isoform H]: Cell membrane
- Lipid-anchor, GPI-anchor
- Extracellular side .
- Golgi apparatus
- Vesicles
- PubMed 11985878
- PubMed 1748670
- Tissue specificity (tau)
- 0.879017
- Expression inequality (Gini)
- 0.626809
Expression in transcripts per million
- Brain - Cerebellum
- 71.17
- Brain - Hypothalamus
- 68.56
- Brain - Cerebellar Hemisphere
- 63.81
- Brain - Nucleus accumbens (basal ganglia)
- 25.14
- Muscle - Skeletal
- 22.4
Expression in transcripts per million
- Brain - Cerebellum71.17
- Brain - Hypothalamus68.56
- Brain - Cerebellar Hemisphere63.81
- Brain - Nucleus accumbens (basal ganglia)25.14
- Muscle - Skeletal22.4
- Brain - Caudate (basal ganglia)22.05
- Brain - Putamen (basal ganglia)18.9
- Brain - Substantia nigra18.73
- Brain - Frontal Cortex (BA9)18.56
- Brain - Cortex18.32
- Brain - Anterior cingulate cortex (BA24)11.66
- Pituitary10.91
- Prostate9.66
- Small Intestine - Terminal Ileum8.69
- Cervix - Endocervix8.18
- Brain - Amygdala7.64
- Brain - Hippocampus7.6
- Testis7.39
- Colon - Transverse7.25
- Brain - Spinal cord (cervical c-1)6.83
- Colon - Sigmoid6.56
- Minor Salivary Gland6.55
- Ovary6.28
- Heart - Atrial Appendage6.16
- Uterus5.62
And 29 more, listed on the interactive page.
- GO:0002076
- GO:0006581
- GO:0007155
- GO:0007399
- GO:0007416
- GO:0032223
- GO:0042982
- GO:0050714
- GO:0005576
- GO:0005794
- GO:0005886
- GO:0016020
- GO:0031594
- GO:0045202
- GO:0048471
- GO:0001540
- GO:0003990
- GO:0004104
- GO:0005515
- GO:0005518
- GO:0016787
- GO:0017171
- GO:0042166
- GO:0042803
- GO:0043236
increased salivation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased salivation
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264death
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: death
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264bronchoconstriction
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: bronchoconstriction
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264muscle relaxation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: muscle relaxation
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264coma
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: coma
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264increased defecation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased defecation
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264vomiting
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: vomiting
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264foot drop
Effects
- Inhibition/Decrease/Downregulation: chronic
Studies
- preclinical: foot drop
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264increased urine excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased urine excretion
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264decreased pupil diameter
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased pupil diameter
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264cognitive deficit
Effects
- Inhibition/Decrease/Downregulation: chronic
Studies
- preclinical: cognitive deficit
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264Decrease, Population growth rate
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Biological samples
- nervous system
Evidence sourceapnea
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: apnea
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264peripheral neuropathy
Effects
- Inhibition/Decrease/Downregulation: chronic
Studies
- preclinical: peripheral neuropathy
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264autonomic dysfunction
Effects
- Inhibition/Decrease/Downregulation: chronic
Studies
- preclinical: autonomic dysfunction
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264mood change
Effects
- Inhibition/Decrease/Downregulation: chronic
Studies
- preclinical: mood change
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264ataxia
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: ataxia
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264lacrimation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: lacrimation
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264tingling/weakness in limbs
Effects
- Inhibition/Decrease/Downregulation: chronic
Studies
- preclinical: tingling/weakness in limbs
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264increased then decreased heart rate
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased then decreased heart rate
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264increased bronchial secretions
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased bronchial secretions
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264convulsions
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: convulsions
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264diarrhea
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: diarrhea
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264Increased Mortality
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Biological samples
- nervous system
Evidence sourceincreased then decreased blood pressure
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased then decreased blood pressure
- nervous system
- respiratory
- cardiovascular
- gastrointestinal
PubMed 28216264
And 1 more, listed on the interactive page.
increased respiratory secretions
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: increased respiratory secretions
- cardiovascular system
- pulmonary
- gastrointestinal
PubMed 23197038decreased gastrointestinal motility
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased gastrointestinal motility
- cardiovascular system
- pulmonary
- gastrointestinal
PubMed 23197038decreased heart rate
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: decreased heart rate
- cardiovascular system
- pulmonary
- gastrointestinal
PubMed 23197038decreased blood pressure
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: decreased blood pressure
- cardiovascular system
- pulmonary
- gastrointestinal
PubMed 23197038regulation of catalytic activity
Studies
- biochemical: NVS_ENZ_hAChE, is one of one assay component(s) measured or calculated from the NVS_ENZ_hAChE assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with absorbance signals by Colorimetric technology.
Biological samples
- cell-free
Evidence sourcebronchoconstriction
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: bronchoconstriction
- cardiovascular system
- pulmonary
- gastrointestinal
PubMed 23197038increased gastrointestinal motility
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: increased gastrointestinal motility
- cardiovascular system
- pulmonary
- gastrointestinal
PubMed 23197038
Related records
Trials (724)
- "Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy"
- 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.
- 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions
- 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients
- A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease
- A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)
- A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
- A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease
- A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment
- A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil
- A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease
- A Bioequivalence Study Comparing Improved Versus Current Orally Disintegrating E2020 10 mg Tablet in Healthy Japanese Adult Males
- A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®
- A Bioequivalence Study of Film-coated Tablet and Dry Syrup 1% Form for E2020 in Healthy Japanese Adult Males
- A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.
- A Clinical Study to Evaluate the Pharmacokinetics (PK) of Corplex™ Donepezil Transdermal Delivery System (TDS) Applied to Different Body Locations
- A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355
- A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003.
- A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type
- A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder
Drugs (41)
- Acotiamide Acetylcholinesterase inhibitor
- Acotiamide hydrochloride Acetylcholinesterase inhibitor
- Ambenonium Acetylcholinesterase inhibitor
- Ambenonium chloride Acetylcholinesterase inhibitor
- Benzgalantamine Acetylcholinesterase inhibitor
- Benzgalantamine gluconate Acetylcholinesterase inhibitor
- Demecarium Acetylcholinesterase inhibitor
- Demecarium bromide Acetylcholinesterase inhibitor
- Distigmine Acetylcholinesterase inhibitor
- Distigmine bromide Acetylcholinesterase inhibitor
- Donepezil Acetylcholinesterase inhibitor
- Donepezil hydrochloride Acetylcholinesterase inhibitor
- Echothiophate Acetylcholinesterase inhibitor
- Echothiophate iodide Acetylcholinesterase inhibitor
- Edrophonium Acetylcholinesterase inhibitor
- Edrophonium chloride Acetylcholinesterase inhibitor
- Galantamine Acetylcholinesterase inhibitor
- Galantamine hydrobromide Acetylcholinesterase inhibitor
- Hexafluorenium Acetylcholinesterase inhibitor
- Hexafluorenium bromide Acetylcholinesterase inhibitor